ROCKVILLE, Md., Aug 24, 2010 (BUSINESS WIRE) --
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company's
Board of Directors appointed John E. Niederhuber, M.D. as a Class III
Director for a two-year term that will expire at the 2012 annual meeting
"Dr. Niederhuber is a nationally renowned surgeon and researcher who has
dedicated his four-decade career to the treatment and study of cancer.
As we expand our portfolio to include cancer therapeutics, his oncology
research and clinical experience will be an invaluable asset in guiding
Emergent's management team towards further growth and in increasing
value for shareholders," said Fuad El-Hibri, chairman and chief
executive officer of Emergent BioSolutions. "We are delighted to welcome
him to Emergent's Board of Directors."
"I am pleased to serve on the Board of a company that has a strong
interest in providing new treatments to cancer patients. Their mission
in vaccine development to protect life aligns closely with my goals to
find life-saving treatments that can benefit patients worldwide," said
Dr. Niederhuber. "I look forward to the opportunity to contribute to
From 2005 to 2010, Dr. Niederhuber served as the director of the
National Cancer Institute (NCI), which is part of the National
Institutes of Health (NIH), one of the largest medical research
institutes in the world. As NCI director, Dr. Niederhuber's
accomplishments include advancing drug and technology innovation and
technology infrastructure, bringing cancer science to patients through
community cancer centers, and working to reduce the inequities of cancer
care. Recently, Dr. Niederhuber joined Inova Health System as Executive
Vice President and CEO of the Inova Institute for Translational Research
and Personalized Medicine. Dr. Niederhuber is also an adjunct
investigator at NCI's Center for Cancer Research. His research focuses
on factors in the tumor microenvironment, in particular on cancer
activated fibroblasts (CAFs) that lead to increased malignancy. As a
surgeon, Dr. Niederhuber's clinical focus has been on gastrointestinal
cancer, hepatobiliary (liver, bile duct, and gallbladder) cancer,
pancreatic cancer and breast cancer.
Prior to coming to NCI, Dr. Niederhuber was Director of the University
of Wisconsin Comprehensive Cancer Center and a professor of surgery and
oncology (member of the McArdle Laboratory) at the University of
Wisconsin School of Medicine. Earlier in his career, he chaired the
Department of Surgery at Stanford University and held professorships at
the Johns Hopkins University School of Medicine and at the University of
Dr. Niederhuber is a graduate of Bethany College in West Virginia and
the Ohio State University School of Medicine. He trained in surgery at
the University of Michigan.
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company focused on the
development, manufacture and commercialization of vaccines and antibody
therapies that assist the body's immune system to prevent or treat
disease. Emergent's marketed product, BioThrax(R) (Anthrax
Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and
Drug Administration for the prevention of anthrax infection. Emergent's
product pipeline targets infectious diseases and includes programs
focused on anthrax, tuberculosis, typhoid, flu and chlamydia. Additional
information may be found at www.emergentbiosolutions.com.
SOURCE: Emergent BioSolutions Inc.
Emergent BioSolutions Inc.
Robert G. Burrows
Vice President, Investor Relations
Vice President, Corporate Communications